Taking Statins on Day of Coronary Bypass Linked to Lower 30-Day Mortality — Physician’s First Watch

Medical News |
March 17, 2017

Taking Statins on Day of Coronary Bypass Linked to Lower 30-Day Mortality

By Amy Orciari Herman

Edited by André Sofair, MD, MPH

Patients undergoing coronary artery bypass grafting (CABG) fare best when they take a statin on the day of surgery, rather than taking one earlier or not at all, according to a retrospective study in the Annals of Thoracic Surgery.

U.S. researchers reviewed the medical records of some 3000 patients who underwent primary CABG at a single institution. Nearly 60% had taken a statin 24 hours or less before surgery, 15% had done so 24–72 hours preoperatively, and the remainder had not taken a statin or had taken one more than 72 hours before surgery.

Thirty-day all-cause mortality was 1.7% with statin use 24 hours or less before CABG, 2.9% with statin use 24–72 hours preoperatively, and 3.8% with statin use 72 hours or more before surgery/no statin use. After multivariable adjustment, only statin use within 24 hours before CABG was independently associated with reduced 30-day mortality.

In terms of dosage, the equivalent of more than 20 mg atorvastatin was independently associated with reduced mortality.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.